Trial Profile
A Phase II Study of MK-2206 for Recurrent Malignant Glioma
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 13 May 2022
Price :
$35
*
At a glance
- Drugs MK 2206 (Primary)
- Indications Glioblastoma; Gliosarcoma
- Focus Biomarker; Pharmacodynamics; Therapeutic Use
- 06 Apr 2011 Status changed from not yet recruiting to withdrawn prior to recruitment, due to Merck undergoing reprioritization of clinical trials, and terminating many in oncology including this one, according to ClinicalTrials.gov.
- 07 Dec 2010 New trial record